Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Georgia sets sights on eliminating hepatitis C

A combination of strong political will, public support and experience gained in HIV prevention and control led to this new programme. The Ministry of Labour, Health and Social Affairs is working with a pharmaceutical manufacturer to provide an initial 5000 courses of DAAs as the first part of the programme, followed by 20 000 treatment courses annually free of charge.

Published
27 July 2015
From
WHO Europe
Viral hepatitis – 400 deaths a day in the WHO European Region could be prevented

Over 13 million people in the WHO European Region are living with chronic hepatitis B infection and over 15 million with chronic hepatitis C infection. Two-thirds of those infected are in eastern Europe and Central Asia. Hepatitis B and C infections lead to 400 deaths in the Region every day.

Published
27 July 2015
From
WHO Europe
FDA approves Technivie for treatment of chronic hepatitis C genotype 4

The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).

Published
27 July 2015
From
FDA
How Sure Is a Cure?

Once you’ve officially rid yourself of hepatitis C, how certain can you be that the virus is gone for good?

Published
20 July 2015
From
Poz
Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

In a bid to push back against payers, Gilead Sciences is limiting enrollment to its patient assistance program for hepatitis C drugs, which helps people obtain the Sovaldi and Harvoni treatments when they lack sufficient insurance coverage or the financial wherewithal to get the medicines otherwise.

Published
20 July 2015
From
Wall Street Journal Pharmalot blog
Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

The drug maker is taking this step after finding that some payers, despite receiving discounts in recent months, have continued to restrict patient access to its hepatitis C medicines. As a result, Gilead has been picking up the cost of the medicines for more people it would like seeking patient assistance, according to a July 1 letter sent to patient groups and community health providers, among others.

Published
19 July 2015
From
Wall Street Journal
Improving access to, and completion of, hepatitis C treatment

PHE's latest briefing in the 'Turning evidence into practice' series has practical advice for commissioners and services on improving access to, and completion of, hepatitis C treatment. Preventing blood-borne virus transmission is one of the eight good practice outcomes of the national drug strategy and treating hepatitis C infection is a growing priority for the NHS.

Published
17 July 2015
From
Public Health England
Gilead pills priced at $1,000 a day are found cost-effective

Health insurers that have been reluctant to cover hepatitis C drugs with list prices of $1,000 a daily dose will face more pressure after a report concluding the medications are “cost-effective” given their benefits.

Published
14 July 2015
From
Bloomberg
National study finds life-threatening barriers in access to breakthrough drugs

Most states violate federal Medicaid law because they deny coverage for sofosbuvir, a new and highly effective treatment to cure hepatitis C, according to Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection Program. Taylor's team of researchers examined Medicaid policies for hepatitis C virus treatment using sofosbuvir and found that most should change policy to improve access to the treatment.

Published
30 June 2015
From
Eurekalert
FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

Specifically, the groups hope to learn about different responses that different patients experienced during clinical trials. Tracy Swan of Treatment Action Group points to relapses in a Harvoni clinical trial that occurred only among African-Americans. The groups also want to perform an independent analysis of poor prognostic factors among people who were not cured in order to identify a patient profile.

Published
29 June 2015
From
Wall Street Journal (blog)
← First12345...61Next →

Filter by country